Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
TUSTIN, Calif., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of previously treated non-small cell lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Contacts: Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 [email protected] Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
